XML 56 R26.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaborative Arrangements and Licensing Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Biogen [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
SPINRAZA royalties (commercial revenue) |  | $ | 267.8 |  |  | $ | 286.6 |  |  | $ | 293.0 |
R&D revenue |  |  | 161.0 |  |  |  | 122.0 |  |  |  | 180.6 |
Total revenue from our relationship with Biogen |  | $ | 428.8 |  |  | $ | 408.6 |  |  | $ | 473.6 |
Percentage of total revenue |  |  | 53 | % |  |  | 56 | % |  |  | 42 | %
AstraZeneca [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
R&D revenue |  | $ | 254.6 |  |  | $ | 88.0 |  |  | $ | 28.1 |
Percentage of total revenue |  |  | 31 | % |  |  | 12 | % |  |  | 3 | %
Bayer [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
R&D revenue |  | $ | 1.1 |  |  | $ | 3.2 |  |  | $ | 14.3 |
Percentage of total revenue |  |  | 0 | % |  |  | 0 | % |  |  | 1 | %
GSK [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
R&D revenue |  | $ | — |  |  | $ | 0.2 |  |  | $ | 25.4 |
Percentage of total revenue |  |  | — |  |  |  | 0 | % |  |  | 2 | %
Novartis [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
R&D revenue |  | $ | 25.5 |  |  | $ | 1.0 |  |  | $ | 187.4 |
Percentage of total revenue |  |  | 3 | % |  |  | 0 | % |  |  | 17 | %
Roche [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
R&D revenue |  | $ | 17.2 |  |  | $ | 5.9 |  |  | $ | 57.0 |
Percentage of total revenue |  |  | 2 | % |  |  | 1 | % |  |  | 5 | %
Alnylam [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Alnylam (in millions, except percentage amounts):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
R&D revenue |  | $ | — |  |  | $ | 47.9 |  |  | $ | 24.1 |
Percentage of total revenue |  |  | — |  |  |  | 7 | % |  |  | 2 | %

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BayerCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_GlaxoSmithKlineCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_NovartisCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_RocheCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AlnylamPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |